Macular Degeneration Treatment Market Poised for Significant Growth, Projected to Reach 7.4% CAGR by 2032 - Insights from Persistence Market Research

The global macular degeneration treatment market is witnessing significant growth, driven by an aging population, increased prevalence of retinal diseases, and advancements in drug development. The treatment options for macular degeneration, particularly age-related macular degeneration (AMD), have evolved rapidly in recent years, with anti-vascular endothelial growth factor (anti-VEGF) therapies leading the charge. As the global population ages and the burden of ocular diseases grows, the demand for effective treatments for macular degeneration is expected to rise sharply, contributing to a robust market expansion.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/33174

Market Statistics and Key Growth Drivers

As of 2022, the macular degeneration treatment market was valued at approximately US$ 9.2 billion. Projections show the market is poised to grow at a 7.4% compound annual growth rate (CAGR), reaching an estimated value of US$ 18.8 billion by 2032. Key factors contributing to this growth include rising incidences of age-related macular degeneration, increasing life expectancy, growing awareness of eye health, and innovations in treatment options such as anti-VEGF drugs. The anti-VEGF class alone held a dominant market share of 60.8% in 2021, illustrating the widespread adoption and effectiveness of these therapies in managing AMD.

The market's growth is also significantly influenced by rising research and development (R&D) investments and regulatory approvals for new treatments. For example, the approval of long-acting anti-VEGF drugs has the potential to drive revenue by reducing the frequency of eye injections, which is a significant concern for patients undergoing current treatments. In addition, the emergence of gene therapies, such as GT005, further supports market growth by offering more sustainable treatment solutions for AMD.

Leading Segment and Geographical Insights

Among the different segments, the wet age-related macular degeneration (wet AMD) category dominates the macular degeneration treatment market. In 2021, this segment accounted for 79.3% of the market share due to the higher prevalence of wet AMD compared to dry AMD. Wet AMD is characterized by abnormal blood vessel growth beneath the retina, which leads to rapid vision loss and requires frequent medical intervention. Anti-VEGF drugs are currently the most effective treatment for this condition.

Geographically, North America stands out as the leading region for the macular degeneration treatment market, particularly driven by the U.S. market, which accounted for 91.8% of the North American market in 2021. The U.S. is home to a large elderly population, and the presence of major pharmaceutical companies focused on developing innovative therapies has made it a central hub for macular degeneration treatment advancements. The high healthcare expenditure and favorable government policies further boost market growth in this region. Additionally, Europe, with its aging population and high prevalence of AMD, also represents a substantial market share, particularly in the U.K. and Germany.

Key Highlights from the Report

✦ The global macular degeneration treatment market is projected to reach US$ 18.8 billion by 2032, growing at a 7.4% CAGR.
✦ Anti-VEGF therapies accounted for 60.8% of the market share in 2021, with wet AMD treatments leading the market.
✦ The U.S. remains the dominant region, contributing 91.8% to the North American market share.
✦ The market is driven by an aging global population and increasing prevalence of retinal diseases.
✦ Long-acting anti-VEGF drugs are expected to create new growth opportunities.
✦ Gene therapies are emerging as a promising treatment option, with products like GT005 receiving regulatory attention.

Market Segmentation

Product Type and Treatment Modalities
The macular degeneration treatment market can be segmented based on product types, such as anti-VEGF therapies, steroid therapies, gene therapies, and surgical procedures. Among these, anti-VEGF drugs hold the largest market share, as they are the primary treatment for wet AMD, which is the most common and aggressive form of the disease. Anti-VEGF drugs like Lucentis, Eylea, and Avastin have revolutionized AMD treatment by preventing the growth of abnormal blood vessels that lead to vision loss.

In addition to anti-VEGF therapies, gene therapies are gaining attention as a long-term solution for patients suffering from macular degeneration. For instance, GT005, a gene therapy treatment for geographic atrophy, is showing promising results in clinical trials and may become a game-changer in the industry. Surgical interventions, although less common, are also used for some forms of macular degeneration, particularly in cases where drug therapy is not effective.

End-User Segmentation
The end-user segmentation of the market includes hospitals, clinics, ophthalmology centers, and home healthcare settings. Hospitals and specialized ophthalmology clinics dominate the market due to the availability of advanced diagnostic tools and the ability to administer treatments like intravitreal injections. However, the rise of home healthcare settings and mobile eye care services has opened up new avenues for patient care, particularly for those who require long-term management of the condition.

Regional Insights

North America
North America is expected to continue its dominance in the macular degeneration treatment market throughout the forecast period. The U.S., in particular, is witnessing a high incidence of age-related eye diseases, primarily due to the aging population. Government initiatives aimed at promoting awareness and funding research on macular degeneration, as well as the presence of leading pharmaceutical companies, makes this region a significant player. Additionally, high healthcare expenditure and advanced healthcare infrastructure further contribute to the market's growth.

Europe
Europe is another key region in the macular degeneration treatment market, with countries like the U.K., Germany, and France seeing a high prevalence of AMD, especially among the elderly population. The market in this region is also supported by favorable reimbursement policies and increasing government focus on combating eye diseases. The U.K., with a significant number of individuals suffering from macular degeneration, particularly wet AMD, remains a key market.

Asia-Pacific
In the Asia-Pacific region, China stands out as a rapidly growing market due to its vast population and increasing aging demographic. China accounted for 42.7% of the East Asian macular degeneration treatment market in 2021. The rising adoption of treatments and a growing awareness of eye health are major factors contributing to the market's growth in this region.

Market Drivers

The macular degeneration treatment market is being driven by several factors, including the increasing prevalence of retinal diseases, an aging population, and advances in therapeutic technologies. Age-related macular degeneration (AMD) is the leading cause of vision impairment and blindness worldwide, particularly in the elderly population. As the global population ages, the number of people suffering from AMD is expected to rise, thereby increasing the demand for effective treatment options.

Additionally, rising research and development investments by pharmaceutical companies are accelerating the discovery of new treatment modalities. The approval of long-acting anti-VEGF drugs and emerging gene therapies are further propelling market growth. These innovations offer patients more convenient and sustainable treatment options, reducing the need for frequent injections and improving adherence to therapy.

Market Restraints

Despite the promising growth prospects, the macular degeneration treatment market faces challenges that may slow its expansion. The high cost of treatment, especially for patented drugs like Lucentis and Eylea, is a significant barrier, particularly in low-income regions. The high cost of these therapies puts a strain on healthcare systems and may lead to limited access to treatment for a large segment of the population.

Furthermore, the patent expiration of leading drugs like Lucentis is expected to introduce competition from biosimilars, potentially lowering the prices of treatments but also creating market uncertainty for established players.

Market Opportunities

The macular degeneration treatment market presents significant opportunities for growth, particularly through the development of long-acting anti-VEGF drugs and gene therapies. These therapies offer the potential to reduce the frequency of injections, improving patient adherence and reducing the burden of treatment. Companies that invest in the development of these innovative solutions will likely see substantial returns.

Another opportunity lies in the emerging markets of Asia-Pacific and Latin America, where rising incomes, increased awareness of eye health, and improved healthcare infrastructure are driving demand for treatments. Expansion into these regions will be crucial for companies looking to tap into new revenue streams.

Reasons to Buy the Report

✔ Gain comprehensive insights into the macular degeneration treatment market trends and forecasts.
✔ Understand the key drivers, challenges, and opportunities that are shaping the market landscape.
✔ Access detailed information on market segmentation, including product types, end-users, and regions.
✔ Analyze the competitive landscape and gain insights into the strategies of leading market players.
✔ Receive a detailed analysis of regional market dynamics, with a focus on North America, Europe, and Asia-Pacific.

Company Insights

• Regeneron Pharmaceuticals, Inc.
• Novartis AG
• Bayer AG
• Roche Holding AG
• Allergan (AbbVie Inc.)

Recent Developments
Bausch Health Companies partnered with the non-profit organization "Preventing Blindness" to raise awareness about macular degeneration.

Gyroscope Therapeutics received fast-track designation from the FDA for their GT005 gene therapy for the treatment of geographic atrophy.

Conclusion

The macular degeneration treatment market is experiencing significant growth driven by an aging population, rising prevalence of retinal diseases, and advancements in treatment technologies. With continued innovation in drug development, particularly long-acting anti-VEGF therapies and gene therapies, the market is set to experience further expansion in the coming years. However, challenges such as high treatment costs and the expiration of patents may pose hurdles. As the demand for effective treatments rises, the market presents ample opportunities for growth, particularly in emerging regions like Asia-Pacific.

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web:
https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.